The pharmaceutical industry is witnessing significant progress in peptide-based therapeutics, with advancements in formulation technologies transforming the delivery landscape. The 2nd Peptide Formulation & Delivery Innovation Summit, scheduled for June 24-26, 2025, in Boston, Massachusetts, aims to address persistent challenges in the field and accelerate the path to commercialization.
Breakthrough Technologies Driving Peptide Delivery Innovation
Recent developments in permeation enhancers, nanoparticle encapsulation, and structural modification capabilities have made oral delivery and improved bioavailability of peptide-based therapeutics a clinical reality. These advancements are encouraging more drug developers to pursue peptide therapeutics, though significant formulation and delivery challenges remain.
The summit positions itself as the only industry-specific event focused on helping pharmaceutical companies overcome formulation and delivery obstacles for peptide-based drugs. With 18 industry expert speakers from leading pharmaceutical and biotech companies, the event promises to deliver valuable insights for professionals working in this specialized field.
Key Sessions and Industry Participation
Several high-profile sessions are planned for the three-day summit. Eli Lilly will present on predicting the translatability of discovery and preclinical systems into humans, a critical step in accelerating peptides into clinical trials.
A session on innovative technologies for oral delivery will feature presentations from AltrixBio, Divincell, and Aviceda Therapeutics, focusing on approaches to achieve double-digit peptide bioavailability—a significant challenge in peptide drug development.
Novo Nordisk and the University of Miami will discuss considerations for high-concentration subcutaneous or multi-dose peptide injectables, as well as analytical development challenges that researchers face in this area.
Expanding Delivery Routes for Broader Applications
The summit will also explore alternative delivery routes beyond oral and injectable formulations. Neurelis and Carocell Bio will present on pushing the limits of peptide formulation through inhaled and intradermal delivery methods to maximize pan-disease applications.
Clinical-stage biotechnology companies, including Xeris Pharmaceuticals and Neuraly, will share their experiences and considerations regarding peptide formulation and delivery from the perspective of organizations actively advancing candidates through clinical development.
Addressing Patient-Centric Concerns
Beyond the technical aspects of formulation, the summit will address the critical issue of patient adherence. As peptide therapeutics gain market share from more established drug modalities, enhancing patient compliance becomes increasingly important for commercial success.
The comprehensive program covers oral, inhaled, intradermal, and parenteral delivery systems, reflecting the diverse approaches being explored in the industry to optimize peptide-based drug delivery without compromising efficacy.
Industry Impact and Future Outlook
The summit comes at a pivotal time when peptide therapeutics are increasingly being recognized for their potential advantages over traditional small molecules and biologics in certain therapeutic areas. The ability to effectively deliver these compounds to their targets while maintaining stability and bioavailability remains a key determinant of their clinical and commercial success.
By bringing together experts from across the pharmaceutical and biotech sectors, the summit aims to foster collaboration and knowledge sharing that could accelerate innovation in peptide drug delivery systems and ultimately benefit patients awaiting new therapeutic options.
